Chinese medicine · 2026
Qishen Granules attenuate adverse ventricular remodeling in chronic heart failure by promoting Legumain/Arg1/Rac1-mediated efferocytosis of resident cardiac macrophages.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tao Meijiao, Min Shixuan, Liu Jiali, Xiao Huishi, Xiao Tong, Liang Sisi, Liu Xin, Wang Jun, Ouyang Yulin, Wen Ruijia, Wang Lei, Wang Wei, Zhang Yao, Li Chun
Аннотация
BACKGROUND: Ventricular remodeling is a key pathological feature of chronic heart failure (CHF). Following myocardial infarction (MI), impaired macrophage efferocytosis sustains cardiac inflammation, disrupts tissue repair, and accelerates adverse remodeling and dysfunction. Qishen Granules (QSG) is a classical traditional Chinese medicine formulation used in the clinical treatment of heart failure. However, its regulatory effects on efferocytosis in resident cardiac macrophages (RCMs) remain unclear.
PURPOSE: This study aimed to elucidate the molecular mechanisms by which QSG regulates Legumain-mediated efferocytosis in RCMs and to identify the key bioactive compounds.
METHODS: A mouse model of post-MI heart failure was established via ligation of the left anterior descending coronary artery. The therapeutic effects of QSG were evaluated in isolated RCMs obtained using magnetic-activated cell sorting. Mechanistic investigations were conducted using transcriptomic analysis, network pharmacology, live-cell imaging, and siRNA-mediated gene silencing. In addition, UPLC-Q-Exactive MS, molecular docking, and molecular dynamics simulations were employed to systematically study the active compounds of QSG.
RESULTS: QSG treatment restored the population of RCMs and enhanced their efferocytic capacity in CHF, thereby reducing cardiomyocyte apoptosis, promoting inflammatory resolution, and improving ventricular structure and function. Mechanistically, QSG upregulated Legumain expression and activated the Arg1/Rac1 signaling axis to facilitate cytoskeletal remodeling and enhance phagocytic efficiency. Further analyses identified tanshinone IIA, neocryptotanshinone and calycosin as the core bioactive compounds of QSG. All three compounds upregulated Legumain expression and exhibited stable binding affinity toward Legumain.
CONCLUSION: QSG restores efferocytic capacity in RCMs by targeting the Legumain/Arg1/Rac1 signaling axis, thereby attenuating adverse ventricular remodeling in CHF.
PURPOSE: This study aimed to elucidate the molecular mechanisms by which QSG regulates Legumain-mediated efferocytosis in RCMs and to identify the key bioactive compounds.
METHODS: A mouse model of post-MI heart failure was established via ligation of the left anterior descending coronary artery. The therapeutic effects of QSG were evaluated in isolated RCMs obtained using magnetic-activated cell sorting. Mechanistic investigations were conducted using transcriptomic analysis, network pharmacology, live-cell imaging, and siRNA-mediated gene silencing. In addition, UPLC-Q-Exactive MS, molecular docking, and molecular dynamics simulations were employed to systematically study the active compounds of QSG.
RESULTS: QSG treatment restored the population of RCMs and enhanced their efferocytic capacity in CHF, thereby reducing cardiomyocyte apoptosis, promoting inflammatory resolution, and improving ventricular structure and function. Mechanistically, QSG upregulated Legumain expression and activated the Arg1/Rac1 signaling axis to facilitate cytoskeletal remodeling and enhance phagocytic efficiency. Further analyses identified tanshinone IIA, neocryptotanshinone and calycosin as the core bioactive compounds of QSG. All three compounds upregulated Legumain expression and exhibited stable binding affinity toward Legumain.
CONCLUSION: QSG restores efferocytic capacity in RCMs by targeting the Legumain/Arg1/Rac1 signaling axis, thereby attenuating adverse ventricular remodeling in CHF.